ANXA9 and neoplasm: G749 treatment resulted in a significantly enhanced anti-tumor effect (Figure 4H,I), as demonstrated by a marked reduction in Ki-67 and ANXA9 expression levels, assessed through immunohistochemistry (IHC) analysis (Figure 4J).